Investment in follow-on biologics may benefit Insmed, Momenta

03/27/2008 | Bloomberg1

The investment of Momenta Pharmaceuticals, Insmed and Cell Therapeutics in technology to develop duplicates of biotech drugs may pay off if Congress allows the sale of follow-on biologics in the U.S. Momenta is working with Novartis AG's Sandoz unit to make a version of Lovenox, Sanofi-Aventis SA's blood thinner, and three other biotech medicines. Cell Therapeutics is working on a technology to simplify production of gene-based drugs, while Insmed will begin human trials of two follow-on biotech treatments this year.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
Bend, OR
Clinical Appeals RN
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ